TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23164314
Drug: Fish oil-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil-based lipid emulsion (FOLE) monotherapy
Study: 23164592
Drug: Elderly patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elderly patients with IPAH receiving combinations of PAH drugs
Study: 28373069
Drug: Crizotinib therapy
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib therapy
Study: 23169503
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin 40 mg/m(2), rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2), vincristine 1.4 mg/m(2), prednisone 100 mg orally on days 1 through 5, with concomitant antiretroviral therapy
Study: 23169518
Drug: High-dose vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vincristine sulfate liposome injection (VSLI) 2.25 mg/m(2), administered once per week until response, progression, toxicity, or pursuit of HCT.
Study: 23170854
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol loading dose (20 mg · kg(-1))
Study: 23170854
Drug: IV paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV paracetamol monotherapy
Study: 23171508
Drug: Tremelimumab (1-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab (1-hour infusion)
Study: 23171803
Drug: Sodium bicarbonate-based
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate-based hydration (154 mEq/L at 3 ml Kg-1 for one hour followed by 1 ml Kg-1 for six hours) with high-dose N-acetylcysteine (NAC)
Study: 23171803
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline hydration (1 ml Kg-1 for 24 hours) with high-dose N-acetylcysteine (NAC)
Study: 23171803
Drug: Sodium bicarbonate-based
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate-based hydration with high-dose NAC
Study: 23171803
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline hydration with high-dose NAC
Study: 23178951
Drug: Amuvatinib dry
Normalized name: Amuvatinib
DrugBank: Amuvatinib (DB12742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amuvatinib dry powder capsules (DPC) 100 to 1,500 mg daily in 28-day cycles
Study: 23178951
Drug: Amuvatinib dry
Normalized name: Amuvatinib
DrugBank: Amuvatinib (DB12742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amuvatinib dry powder capsules (DPC)
Study: 23179335
Drug: Aflibercept 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 2.0 mg/kg with FOLFIRI
Study: 23179335
Drug: Aflibercept 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflibercept 4.0 mg/kg with FOLFIRI
Study: 23179562
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ketorolac tromethamine (at delivery)
Study: 23180239
Drug: Acute hyperglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute hyperglycemia (PG 231.5 ± 18.1 mg/dl)
Study: 23180239
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance assessed by glucose infusion rate (GIR; mg/kg/min)
Study: 23180507
Drug: Intravenous/oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous/oral moxifloxacin (MXF, N = 110) 400 mg q.d.
Study: 23180507
Drug: Intravenous piperacillin/tazobactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous piperacillin/tazobactam 4.0/0.5 g t.d.s. followed by oral amoxicillin/clavulanate 875/125 mg b.d. (PIP/TAZ-AMC, N = 96)
Study: 23182663
Drug: Sunitinib 50mg
Normalized name: sunitinib 50 MG
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sunitinib 50mg p.o. daily for 4 weeks followed by 2 weeks off (6-week cycle)
Study: 23183434
Drug: PEGIFN AUC
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGIFN AUC >0.79 mg · h/liter
Study: 23183434
Drug: PEGIFN cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGIFN cumulative 1-week AUC ≤0.79 mg · h/liter
Study: 23186915
Drug: Self-sufficiency determined
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-sufficiency determined with established score systems (instrumental activities of daily living score, Barthel Index)
Study: 23186936
Drug: Treatment at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at discharge for patients with reduced LVEF included ACE inhibitors/ARBs (78%), beta-blockers (67%), and aldosterone inhibitors (27%).
Study: 23190183
Drug: IFN-γ-1b (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-γ-1b (100 μg three times per week) added to PEG-IFN-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 32 weeks after initial 16 weeks of dual therapy.
Study: 23190183
Drug: PEG-IFN-α-2a (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-IFN-α-2a (180 μg/week) and ribavirin (1000-1200 mg/day) for 16 weeks (initial dual therapy).
Study: 23190221
Drug: Ponatinib (AP24534)
DrugBank: Ponatinib (DB08901)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ponatinib (AP24534) administered once daily at doses ranging from 2 to 60 mg.
Study: 23193189
Drug: High physiological
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High physiological testosterone gel
Study: 23193189
Drug: Low physiological
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low physiological testosterone gel
Study: 23193189
Drug: Castrate levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Castrate levels of testosterone (induced by gonadotropin-releasing hormone agonist treatment)
Study: 23194380
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate 500 μg twice a day
Study: 23194380
Drug: Chromium therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chromium therapy
Study: 23194482
Drug: Prediction rules
Normalized name: Rubes nigrum seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction rules developed from prospectively gathered evaluation and treatment data in the acute setting (STRATIFY) and early inpatient stay (DECIDE)
Study: 23194482
Drug: Comprehensive cardiology
Normalized name: Cardiology Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive cardiology review for assigning post-treatment outcomes
Study: 23197081
Drug: Cediranib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib (45 mg single dose followed by 30 mg continuous once-daily for 21 days)
Study: 23197081
Drug: Cediranib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib (30 mg continuous once-daily dosing)
Study: 23197288
Drug: Proton-pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton-pump inhibitor (PPI) treatment
Study: 23197414
Drug: Vaccine trial
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine trial with skin biopsy leaving a 6-cm scar
Study: 23197414
Drug: Vaccine trials
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine trials requiring skin biopsy leaving a 3-cm scar
Study: 23197414
Drug: Vaccine trials
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine trials requiring skin biopsy leaving a 6-cm scar
Study: 23197414
Drug: Vaccine trials
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine trials requiring skin biopsy leaving a 12-cm scar
Study: 23197414
Drug: Vaccine trials
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine trials without biopsy
Study: 23197589
Drug: Intraventricular rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraventricular rituximab (10 mg or 25 mg) administered twice weekly for 4 weeks, with rituximab as monotherapy during the first treatment each week and in combination with methotrexate (MTX) during the second treatment each week.
Study: 23199229
Drug: Prednisolone 75
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 75 mg (protocol 2)
Study: 23199229
Drug: Prednisolone 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 7.5 mg, 15 mg, 30 mg (protocol 1)
Study: 23199229
Drug: Prednisolone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (all doses)
Study: 23199641
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity meeting weekly recommendations
Study: 23199894
Drug: Anti-aggregatory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-aggregatory therapy
Study: 23199894
Drug: Cytoreductive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive treatment patterns
Study: 23200268
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity warfarin therapy
Study: 23207876
Drug: Losartan (0.44-2.23
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (0.44-2.23 mg/kg/day)
Study: 23207876
Drug: Enalapril (0.07-0.72
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (0.07-0.72 mg/kg/day)
Study: 23208833
Drug: Oseltamivir 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 150 mg administered nasogastrically or nasoenterically every 12 hours
Study: 23210427
Drug: Cotinine model
Normalized name: Chinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotinine model (threshold of 10 ng/ml)
Study: 23211708
Drug: Intratendinous leukocyte-rich
Normalized name: interferon alfa-3n,human leukocyte derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratendinous leukocyte-rich PRP injection
Study: 23211938
Drug: Oral ridaforolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ridaforolimus (40 mg QD × 5 days/week)
Study: 23212718
Drug: 325-mg immediate
Normalized name: aspirin 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325-mg immediate release aspirin
Study: 23212718
Drug: 325-mg enteric
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 325-mg enteric coated aspirin
Study: 23212718
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg low-dose enteric coated aspirin
Study: 23212718
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release aspirin
Study: 23213094
Drug: Foretinib 240
Normalized name: Foretinib
DrugBank: Foretinib (DB12307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foretinib 240 mg once per day on days 1 through 5 every 14 days (intermittent arm)
Study: 23213094
Drug: Foretinib 80
Normalized name: Foretinib
DrugBank: Foretinib (DB12307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foretinib 80 mg daily (daily dosing arm)
Study: 23216571
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg) and Clopidogrel (600 mg) administered prior to PPCI
Study: 23216716
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU in the morning and afternoon for 6 weeks)
Study: 23216781
Drug: Drug-eluting beads
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting beads delivering irinotecan (DEBIRI)
Study: 23216870
Drug: Deferoxamine (DFO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine (DFO; a slow subcutaneous infusion via portable pump)
Study: 23216870
Drug: Oral chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chelation
Study: 23216870
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (DFO and oral chelation)
Study: 23216870
Drug: Concerns about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concerns about treatment
Study: 23217037
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (AL) tablets (20mg artemether and 120mg lumefantrine)
Study: 23217273
Drug: Oral lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral lenalidomide (5 to 10 mg/day)
Study: 23217964
Drug: AZD5213 (0.05-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5213 (0.05-30 mg)
Study: 23217964
Drug: AZD5213 (1-14
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5213 (1-14 mg/d)
Study: 23222881
Drug: L-PGDS in
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PGDS in severe obstructive sleep apnoea (n = 23)
Study: 23222881
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure treatment for 2 days in severe obstructive sleep apnoea (n = 12)
Study: 23222881
Drug: Morning urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning urinary L-PGDS concentrations
Study: 23225523
Drug: Preendoscopy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preendoscopy treatment
Study: 23225523
Drug: Postendoscopic pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postendoscopic pharmacological therapy
Study: 23226015
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to resolution of exacerbation after treatment initiation
Study: 23226204
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg PO twice daily) plus carboplatin (AUC=6) and paclitaxel (225 mg/m(2)) administered IV on day 1 for up to 6 cycles, followed by sorafenib monotherapy until disease progression
Study: 23227182
Drug: Metabolomic analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metabolomic analysis using a combined direct injection and LC-MS/MS assay (AbsolutIDQ p180 kit)
Study: 23228035
Drug: R115777 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: R115777 administered twice per day for 21 days of a 28-day cycle.
Study: 23228045
Drug: DA-EDOCH14-R (two-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-EDOCH14-R (two-weekly dose-adjusted EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab)
Study: 23228045
Drug: DA-EPOCH-R (3-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: DA-EPOCH-R (3-weekly DA-EPOCH-R)
Study: 23228190
Drug: Imatinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (600 mg QD) combined with cisplatin (60 mg/m(2) d1 q 3w) and capecitabine (1250 mg/m(2) bid d1-14 q 21)
Study: 23228190
Drug: Imatinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (600 mg QD) combined with cisplatin (50 mg/m(2) d1 q 2w) and 5-fluoruracil (2 g/m(2) d1, q 1w)
Study: 23228190
Drug: Imatinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (300 mg QD)
Study: 23228190
Drug: Imatinib (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (700 mg QD)
Study: 23228190
Drug: Imatinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (600 mg QD)
Study: 23228190
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (not specified)
Study: 23228990
Drug: 2-deoxy-D-glucose (2DG)
DrugBank: 2-deoxyglucose (DB08831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-deoxy-D-glucose (2DG) at 63 mg/kg/day combined with docetaxel at 30 mg/m(2) for 3 of every 4 weeks.
Study: 23228990
Drug: 2-deoxy-D-glucose (2DG)
DrugBank: 2-deoxyglucose (DB08831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-deoxy-D-glucose (2DG) at 63 mg/kg/day
Study: 23229692
Drug: Eyes initially
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eyes initially randomized to treatment
Study: 23230059
Drug: Oseltamivir 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 3.0 mg/kg for infants 0-8 months
Study: 23230059
Drug: Oseltamivir 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 3.5 mg/kg for subjects 9-11 months
Study: 23230059
Drug: FDA-approved unit
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA-approved unit dose of 30 mg for subjects 12-23 months
Study: 23233571
Drug: Salvage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage therapy (specific regimens not detailed)
Study: 23234268
Drug: ReCap Hip
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ReCap Hip Resurfacing System implant (Biomet Inc., Warsaw, USA)
Study: 23237128
Drug: Antithrombotic therapies
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapies during hospitalization and after discharge
Study: 23237128
Drug: Initial combinations
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial combinations of antithrombotic therapies during hospitalization
Study: 23237128
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in antithrombotic treatments during 24-month follow-up
Study: 23240851
Drug: Topotecan delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan delivered via convection-enhanced delivery (CED) at a total dose of 0.403 mg in 6.04 ml over 100 hours for the first patient, and 0.284 mg in 5.30 ml over 100 hours for the second patient.
Study: 23241251
Drug: Guggulsterone (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guggulsterone (oral administration)
Study: 23241455
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs supplementation (1.14 g DHA and 1.56 g EPA from six fish oil capsules per day for twelve weeks)
Study: 23242596
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m2 for 7 days followed by escalating doses of lenalidomide daily for 21 days starting on day 8 of each cycle every 6 weeks
Study: 23242601
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with MTX/IFO/DEP followed by high-dose chemotherapy with carmustine, thiotepa, etoposide, and autologous stem cell transplantation (HD-ASCT)
Study: 23242601
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with carmustine, thiotepa, etoposide, and autologous stem cell transplantation (HD-ASCT)
Study: 23242601
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with MTX/IFO/DEP
Study: 23242601
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with AraC/TT/DEP
Study: 23242601
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with HD-ASCT
Study: 23243055
Drug: Daily temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily temozolomide (50 mg/m2) continuously until progression
Study: 23243282
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg per day on days 1 to 21 of each 28-day cycle
Study: 23243282
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg per day with dexamethasone 40 mg per week
Study: 23243282
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg per day
Study: 23243282
Drug: Dexamethasone 40
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 40 mg per week
Study: 23245284
Drug: Conformal or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conformal or intensity modulated radiation therapy
Study: 23247661
Drug: R-CHOEP-14 followed
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOEP-14 followed by high-dose cytarabine and high-dose methotrexate
Study: 23248254
Drug: Bendamustine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 120 mg/m² as a 30-minute infusion on days 1 and 2 every 28 days with growth factor support
Study: 23248257
Drug: Trametinib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (2 mg orally once daily) in cohort A
Study: 23248257
Drug: Trametinib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trametinib (2 mg orally once daily) in cohort B
Study: 23249699
Drug: Levothyroxine (T4)
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (T4) treatment
Study: 23250892
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml kg(-1) colloid for 10 min
Study: 23250963
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CSF TT and Rout
Study: 23253635
Drug: Tapentadol vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol vs Oxycodone
Study: 23254596
Drug: Amlodipine/Olmesartan (AML/OM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/Olmesartan (AML/OM) 5/20 mg for 4 weeks, followed by uptitration to AML/OM 5/40 mg, AML/OM 10/40 mg, AML/OM 10/40 mg + HCTZ 12.5 mg, and AML/OM 10/40 mg + HCTZ 25 mg at 4-week intervals if BP remained uncontrolled.
Study: 23255310
Drug: Hydroxyurea at
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea at maximum tolerated dose (MTD, 24.4 ± 4.5 mg/kg/day, range 15.3-30.6 mg/kg/day)
Study: 23256542
Drug: 17-allyamino-17-demethoxygeldanamycin (17-AAG)
Normalized name: 2,4-Bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-allyamino-17-demethoxygeldanamycin (17-AAG) 150 mg/m(2) and bortezomib 0.7 mg/m(2)